ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO 21st World Congress on Gastrointestinal Cancer

 

3-6 July 2019 Barcelona
Close
N. Poster
Poster title
Applicant name
Status
  1-SO Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer. Shigenori Kadowaki Received Received
  1-PD Analysis of patient screening in the phase III, international, randomized, open-label APACT trial Michele Reni Received Received
  2-PD CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): biomarker analysis from the randomised phase II SCALOP trial SOMNATH MUKHERJEE Received Received
  2-SO Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-nave advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF) Ian Chau Received Received
  3-LBA A phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study) Yuko Hirano Received Received
  3-PD IDENTIFICATION OF A NANOSTRING SIGNATURE THAT DIFFERENTIATES EARLY PANCREATIC CANCERS ACCORDING TO STROMAL COMPOSITION AND PREDICTS CLINICAL OUTCOME Chiara Braconi Received Received
  3-P Perturbation of fatty acids of erythrocyte membranes and blood serum in patients with colorectal cancer: new opportunities for diagnostics Margarita Kruchinina Received Received
  4-PD Time to CA19.9 nadir: a clue for defining treatment duration of primary chemotherapy in resectable PDAC Umberto Peretti Received Received
  4-P Nine years of epidemiological changes of gastrointestinal cancer in Egypt Rasha Aboelhassan Received Received
  4-O Applied Precision Cancer Medicine in advanced Biliary Tract Cancer Hossein Taghizadeh Received Received
  5-SO A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer Zev Wainberg Received Received
  5-PD Analysis of weight loss as a prognostic factor in patients with advanced gastric cancer from the Phase 3 RAINBOW study Eva Hortas Received Received
  5-P Increased FLVCR1 expression predicts poor prognosis and enhances malignant phenotypes in esophageal squamous cell carcinoma Suna Zhou Received Received
  6-P miR-381-3p inhibits migration and invasion in ESCC through downregulated FLVCR1 wenguang ye Received Received
  6-PD A predictive model for endoscopic ultrasonography accuracy of invasion depth in early gastric cancer Jun Chul Park Received Received
  6-SO Hafnium oxide nanoparticles activated by SBRT: a new interventional radiation therapy approach for the treatment of unresectable liver cancers Omar Vivar Received Received
  7-PD Surgical Indication for advanced gallbladder cancer considering the optimal preoperative carbohydrate antigen 19-9 cut-off value Eva Hortas Received Received
  7-O ZEBRA: An ACCRU/IRCI Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small Bowel Adenocarcinoma (SBA) Katrina Pedersen Received Received
  7-P Rectal cancer in Albania: treatment outcome and prognostic factors of disease progression. Elvisa Kozma Received Received
  7-LBA Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable mCRC Carlotta Antoniotti Received Received
  8-PD Serial circulating tumor DNA (ctDNA) monitoring to predict response to treatment in metastatic gastrointestinal cancers Aparna Parikh Received Received
  9-PD Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC Eva Hortas Received Received
  9-P Prognostic factors of untreated hepatocellular carcinoma on cirrhosis STOIAN MARILENA Received Received
  10-P GLOMERULAR FILTRATION RATE TO LIVER TRANSPLANTATION STOIAN MARILENA Received Received
  10-O VOLTAGE: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer (EPOC 1504) Hideaki Bando Received Received
  10-SO Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors. Isabelle Ahrens-Fath Received Received
  10-PD Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: results of INNOVATE study Andrea Casadei Gardini Received Received
  11-PD Mutational profile of non-metastatic anal squamous cell carcinoma: a restrictive high impact genetic variants analysis Ismael Ghanem Received Received
  12-PD Emerging risk factors of recurrence and overall survival in a Swedish stage I-III colon cancer cohort Erik Osterman Received Received
  12-P Weighted gene co-expression networks explored MiR-92b Implicated In esophageal squamous cell cancer Wanpeng Wang Received Received
  13-PD RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC) Yu Sunakawa Received Received
  13-O Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies Gemma Zucchelli Received Received
  13-P Surgical and combined treatment for patients with cholangiocarcinoma: the experience of FSBI Aleksandr Polyakov Received Received
  14-P Associations between primary cancer site, metastatic site, comorbidity, and details of symptoms and treatment in advanced gastrointestinal cancer patients at end-of-life Shuji Hiramoto Received Received
  15-P Association between prognosis and discontinuation by image diagnosis for advanced gastrointestinal cancer patients who received end-of-life chemotherapy Shuji Hiramoto Received Received
  15-PD Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies Daniele Rossini Received Received
  16-P Long-course chemoradiation in carcinoma rectum; is it really worth it? Perspectives from a developing nation DEEP CHAKRABARTI Received Received
  16-O Serial assessment of cell-free circulating tumor DNA (ctDNA) to assess treatment effect and minimal residual disease during neoadjuvant and adjuvant therapy in colorectal cancer Victoria Raymond Received Received
  16-PD Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study Alessandra Raimondi Received Received
  17-O SUNRISE-DI study: decision impact of the 12-gene recurrence score (12-RS) assay on adjuvant chemotherapy recommendation for stage II and IIIA/B colon cancer Jun Watanabe Received Received
  17-PD APC I1307K and risk of colorectal neoplasia in humans and mice Stephen Gruber Received Received
  18-PD Feasibility of next-generation sequencing of circulating tumor cells for predicting relapse after liver resection in metastatic colorectal cancer KO Lam Received Received
  18-P Prediction of oncologic outcome using systemic neutrophil-to-lymphocyte ratio in stage II and III colon cancer Youn Young Park Received Received
  18-O Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study Elizabeth Alwers Received Received
  19-PD Optimizing treatment with anti-epidermal growth factor receptor drugs for patients with metastatic colorectal cancer: novel mechanisms of resistance beyond RAS Claudia Cardone Received Received
  19-P Chemotherapeutic hyperthermic intraperitoneal perfusion following radical D2 resection in the treatment of advanced gastric cancer lucheng Zhu Received Received
  20-PD Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identify a heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC) Rahul Das Received Received
  20-O Copy number variation in longitudinal liver metastases biopsies in colorectal cancer identifies biomarker candidates of resistance to standard chemotherapy Karen Gambaro Received Received
  20-P Surprisingly high prevalence of DPYD gene mutation in UK regional trust: implications for treatment Samantha Kestenbaum Received Received
  21-PD Bevacizumab (BV) maintenance after first-line chemotherapy plus BV for metastatic colorectal cancer patients: a meta-analysis of individual patients data from 3 phase III studies Eva Hortas Received Received
  21-P Efficient treatment policies and its impact on the economic burden for CRC in low-middle income countries: the Egypt Case Abdalla Abotaleb Received Received
  22-PD PARP-ness in Metastatic Colorectal Cancer Gianluca Mauri Received Received
  22-P Which patients on chemotherapy for colorectal cancer should be anticoagulated? Samantha Forner Received Received
  22-O Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC) Donna Stefanoni Received Received
  23-PD Survey on the Unmet Needs of Patients Living with mCRC Learnings from an International Study Zorana Maravic Received Received
  24-PD Exploratory analysis of the effect of FTD/TPI in mCRC patients treated in RECOURSE by different prognostic factors: impact on ECOG PS Sarah Novack Received Received
  25-O A randomized, multicenter, phase II trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients filippo pietrantonio Received Received
  25-PD Hand-foot syndrome is a biomarker of improved survival following treatment with capecitabine Claire Palles Received Received
  25-P Toxicity syndromes, patient-related clinical indicator of toxicity burden induced by intensive triplet chemotherapy-based regimens in metastatic gastrointestinal cancers Gemma Bruera Received Received
  26-O Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC) Inma Ruiz de Mena Received Received
  26-PD Quality of life in patients treated with aflibercept and FOLFIRI for metastatic colorectal cancer: interim analysis with focus on therapy lines of the non-interventional study QoLiTrap (AIO-LQ-0113) Ralf Hofheinz Received Received
  27-PD Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis Daniele Rossini Received Received
  27-P Multidirectional colonoscopy quality improvement increases adenoma detection rate: results of the Seoul national university hospital healthcare system Gangnam center colonoscopy quality upgrade project (Gangnam-CUP) Ji Yeon Seo Received Received
  28-PD Pattern and dynamics of metastatic sites during course of metastatic colorectal cancer (mCRC) trajectory in 1086 Finnish patients in the nationwide prospective RAXO study. Pia Osterlund Received Received
  29-P Impact on survival of local complications in Pancreatic Cancer: experience at the Ramón y Cajal University Hospital (HURyC) Juan Jose Serrano Domingo Received Received
  29-PD Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer OPEN Health Medical Communications Received Received
  30-PD Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC) Michael Geissler Received Received
  30-P Serglycin level in peripheral circulating blood cells has prognostic significance in patients with hepatocellular carcinoma Hongjie Chen Received Received
  31-PD Immune signatures identify three immune clusters in mCRC, with potential clinical implications Leire Pedrosa Received Received
  31-P Low level of centromere-associated protein E promotes growth of hepatocellular carcinoma and is associated with adverse clinical features Yiguang Lin Received Received
  32-PD Comparison of surgical data and survival outcome of rectal cancer patients that need upfront surgery after chemoradiotherapy versus salvage surgery after watch-and-wait Philippe Bulens Received Received
  32-P Hypofractionated volumetric modulated arc therapy (VMAT) in the treatment of advanced oesophageal cancer. Letizia Deantonio Received Received
  33-PD A prospective cohort study on the effect of radiotherapy for rectal cancer on female sexual function Annika Svanstrm Rjvall Received Received
  34-PD Clinical outcomes of rectal neuroendocrine tumors less than 20 mm: a single institutional analysis of 371 patients Eva Hortas Received Received
  34-P PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer Alison Sinclair Received Received
  35-P Prognosis of gastric dysplasia according to mucin phenotype after complete resection with endoscopic procedures Jin-Oh Kim Received Received
  36-P Multidisciplinary approach associated with improved overall survival in metastatic colorectal cancer JOLANTA ZOK Received Received
  37-P Doxycycline as a preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy: interim analysis to evaluate skin toxicities. Juan Luis Sanz Received Received
  39-P ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: results of a prospective single centre clinical utility study (PRECISE STUDY) Thomas Starkey Received Received
  40-P Cost of metastatic colorectal cancer drugs per month of life gained in Spain silvina grasso Received Received
  41-P Predictivity of body mass index, age and tumor laterality for systemic therapy outcome in metastatic colorectal cancer patients Amer Radwi Received Received
  43-P Scope position is a determining factor for diagnostic performance of EUS-FNA for mass lesions in the pancreas head and uncinate process Nam Hee Kim Received Received
  46-P Expression pattern of death receptors FasR and DR3 on NK and T cells defines the complexity of tumor-immune system interplay in esophageal cancer Martin Snajdauf Received Received
  50-P The Velindre cancer centre experience of panitumumab versus cetuximab in combination with chemotherapy for metastatic colorectal cancer: a comparison of toxicity and economic evaluation. Amy Case Received Received
  51-P Predictors of response to 3rd line TAS-102 chemotherapy in metastatic colorectal cancer Vasileios Angelis Received Received
  53-P Neoadjuvant rectal cancer (NAR) score as a prognostic factor in locally advanced rectal cancer patients in Assiut university hospital clinical oncology department Mariam khalil Received Received
  54-P Retrospective analysis of the efficacy and safety of regorafenib in patients with advanced GIST Hiroshi Nakatsumi Received Received
  57-P Interleukin-6 correlated with neutrophil-to-lymphocyte ratio in pancreatic cancer Pop Vlad Vasile Received Received
  58-P Trifluridine/tipiracil safety and efficacy in Russian patients with metastatic colorectal cancer and refractory or intolerant to standard chemotherapies: Results of the primary analysis. Sarah Novack Received Received
  59-P SM-88 therapy in high-risk poor prognosis pancreatic cancer (PDAC). Maria Loushin Received Received
  60-P Outcomes for 556 consecutive patients with stages I-III colon cancer managed in a single cancer center in Cyprus over 10 years Eleni Xenophontos Received Received
  62-P Predicting esophageal cancer outcome with positron emission tomography using deep convolutional neural network Po-Kuei Hsu Received Received
  63-P ROLE OF MAINTENANCE GEMCITABINE IN ADVANCED/METASTATIC CARCINOMA GALL BLADDER MANISH SHARMA Received Received
  64-P Self-expandable metal stent (SEMS) for esophageal-gastric junction versus pyloric area obstruction in advanced gastric cancer patients: a retrospective, comparative, single-center study Hee Seok Moon Received Received
  65-P A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study Junichi Nakazawa Received Received
  66-P Neutrophil/lymphocyte ratio in metastatic colorectal cancer: real-world data for evidence of its prognostic role Gonalo Nogueira-Costa Received Received
  69-P Acute pancreatitis after pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in an ongoing phase 1 study for peritoneal metastasis Guowei Kim Received Received
  70-P Esophageal cancer: 5 years of experience in a Mexican oncology reference center. Carlos Eduardo Salazar-Mejía Received Received
  72-P Effects of natural substances from Boswellia sacra and Nerium oleander (breastin) in colon and pancreatic cancer PANAGIOTIS PARSONIDIS Received Received
  73-P Oxaliplatin-based chemotherapy in patients aged at least 75 years with metastatic colorectal cancer: a post-hoc subgroup analysis if three phase II studies Gerardo Rosati Received Received
  74-P A three-year study of epidemiological trends of gastrointestinal cancers in a Haitian cancer program Doukens Patrick Gilbert Received Received
  75-P SBRT in primary and metastatic liver disease: analysis after implementation in our center Carolina De la Pinta Received Received
  76-P Adjuvant chemotherapy for stage II colon cancer: the prognostic value of high-risk features Chinock Cheong Received Received
  78-P Preoperative neutrophil to lymphocyte ratio as a prognostic factor for patients with colorectal cancer Ivica Zarev Received Received
  80-P Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase II trial (PRODIGE 58 UCGI 35 REGIRI) Laure Monard Received Received
  82-P Efficacy and safety of intermittent dosing schedule of apatinib for advanced gastric cancer in second-line setting Yifu He Received Received
  83-P FLOT- or CROSS-protocol treatment in advanced adenocarcinoma of the esophagus: a retrospective single-center analysis Jonas Herzberg Received Received
  85-P Rectal adenocarcinoma: clinical predictive factors for tumor response after chemoradiotherapy Carolina De la Pinta Received Received
  86-P EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment Merissa Lee Received Received
  88-P Radiology-guided oesophageal stenting for the palliation of dysphagia: a single center experience Rajarshi Roy Received Received
  89-P FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial Yara Torres Received Received
  92-P Impact on survival of adjuvant chemotherapy following chemo-radiotherapy and surgery in locally advanced, non-metastatic rectal adenocarcinoma: a retrospective analysis among 331 patients Marion SONDAG Received Received
  93-P Male gender and bone metastases linked to inferior survival in advanced biliary tract cancer Felipe Oliveira Received Received
  95-P Gastroenteropancreatic neuroendocrine neoplasia G3 according to 2017 WHO classification: a comprehensive clinicopathological characterization including mismatch repair proteins and PDL1 expression in a large cohort of patients Julieta Grasselli Received Received
  99-P Triplet chemotherapy plus cetuximab as first-line treatment in RAS wild-type metastatic colorectal carcinoma patients Emmanuelle SAMALIN Received Received
  100-P Trifluridine-tipiracil for the treatment of metastatic colorectal cancer patients: UK multicentre real-world experience Michael Tilby Received Received
  101-P A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy Alessandro Parisi Received Received
  102-P Phase II study of neoadjuvant chemotherapy with S-1 plus oxaliplatin at a dose of 130mg/m2 (nacG-SOX130) in clinical(c)Stage III gastric cancer. Sayuri Konishi Received Received
  103-P Prognostic implications of free cancer cells in gastric juice in gastric cancer patients who underwent surgery: a prospective cohort study Dai Manaka Received Received
  104-P Potent anticolorectal cancer activity of 5-fluorouracil and laccaic acid combination via modulation of epigenetic regulation Riya Gupta Received Received
  108-P Quality of life assessment and reporting in colorectal cancer: a systematic review of phase III trials published between 2012 and 2018 Pasquale Lombardi Received Received
  112-P A retrospective study on treatment outcomes for patients with high grade neuroendocrine colorectal carcinoma. PAVLOS PISKILIDIS Received Received
  114-P Relationship between peripheral neuropathy and effectiveness in second-line chemotherapy for unresectable advanced gastric cancer: a prospective, observational, multicenter study protocol HIROAKI TANIOKA Received Received
  115-P The onset of grade = 3 neutropenia at the first cycle is associated with longer overall survival in metastatic colorectal cancer patients treated with trifluridine/tipiracil Jacopo Giuliani Received Received
  116-P GRADE evaluation of the COLOFOL randomized clinical trial Eduardo Ceballos Received Received
  117-P Stage IIa colon cancer: adjuvant chemotherapy in real life Renato Cunha Received Received
  123-P A Retrospective Qualitative Pilot Study Incorporating Patient Personal Life Aspects upon Admission to Palliative Care: What should we know about patients to give them the best care possible? Anna Kitta Received Received
  124-P Definitive chemoradiotherapy in oesophageal cancer: Treatment outcomes from a regional cancer centre Mohammed Abdul-Latif Received Received
  125-P Total neoadjuvant treatment of ugly rectal cancers in Slovenia Vaneja Velenik Received Received
  126-P The management of pancreatic adenocarcinoma in a hospitalized-based population (2015-2019) aicha bengueddach Received Received
  128-P Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease. Michele Ghidini Received Received
  129-P Expression of female sex hormone receptors, connective tissue growth factor, and HER2 in gallbladder cancer and adjacent normal tissue RENATA DUCHNOWSKA Received Received
  130-P Factors associated with the efficacy of aflibercept in patients with metastatic colorectal cancer: results of the multicenter observational study Mikhail Fedyanin Received Received
  132-P A novel LncRNA (LOC105371049) regulates colorectal cancer proliferation, metastasis and metabolism hongyan yu Received Received
  133-P A randomized, multicenter, open-label controlled phase II trial of Foxy-5 as neoadjuvant therapy in patients with WNT5A negative colon cancer Peter Morsing Received Received
  134-P Real-world guideline application in the management of pancreatic cancer patients: the Italian GARIBALDI study Michele Reni Received Received
  136-P Effect of regorafenib in delaying definitive deterioration in health-related quality of life across three tumor types Ralf Hofheinz Received Received
  137-P Circulating T cell subsets differ in PDAC patients at initial diagnosis and after two months of treatment: a single institution prospective study Skaiste Tulyte Received Received
  138-P Alcohol consumption and tobacco smoking and ed gastrointestinal cancers morbidity rates in Poland Miroslaw Jarosz Received Received
  139-P Chemotherapy Rechallenge or Reintroduction (CTr/r), Regorafenib (REG) and TAS-102 for metastatic pretreated colorectal cancer (mCRC) patients: a PROpensity ScorE analysis of tReatment beyond the second liNe (PROSERpINa Study). Maria Alessandra Calegari Received Received
  140-P Correlation between values of specific biomarkers and outcome in metastatic colorectal cancer patients treated with regorafenib VINCENZO RICCI Received Received
  142-P Sunitinib rechallenge in pancreatic neuroendocrine tumors Vasiliki Michalaki Received Received
  143-P Gastric cancer: system approach Oleg Kshivets Received Received
  144-P Impact of ileostomy in the adjuvant treatment of colorectal cancer stages II-III German Calderillo Received Received
  145-P Gastric cancer in young Latin women: bad prognostic factors and outcomes. German Calderillo Received Received
  147-P Surgery specialization as a prognostic factor in colon cancer German Calderillo Received Received
  149-P High rates of hepatocellular carcinoma within two years of starting treatment for chronic hepatitis C with direct antiviral agents but not with PEG-interferon/ Ribavirin (HORRID Study) Alexander Siebenhuener Received Received
  150-P Perioperative FLOT experience: pathological regression and toxicity Adrián Sánchez Received Received
  154-P Correlation between neutrophil/lymphocyte ratio and postoperative infectious complications after pancreatoduodenectomy for carcinoma of the pancreas head Lucia Romano Received Received
  156-P Treatment for esophageal and esophagogastric junction cancer with radical radiotherapy: a single-institution cohort study Vesna Bisof Received Received
  157-P Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen. Nieves Martinez-Lago Received Received
  158-P Patient understanding of the aim and duration of treatment during the consent process Gireesh Kumaran Received Received
  159-P Patterns and predictors of relapse following radical chemoradiotherapy delivered using intensity-modulated radiotherapy with a simultaneous integrated boost in anal squamous cell carcinoma. Rebecca Muirhead Received Received
  160-P Updated results of a phase II randomized trial with high dose proton pump inhibitors and metronomic capecitabine as salvage treatment for patients with advanced gastrointestinal tumours giulia arrivi Received Received
  162-P Dose-escalated intensity-modulated radiotherapy (IMRT) using a simultaneous integrated boost (SIB) in rectal cancer Rebecca Muirhead Received Received
  163-P Whole-exome sequencing of non-metastatic anal squamous cell carcinoma: a prognostic genetic variants analysis Ismael Ghanem Received Received
  166-P Systemic inflammatory response index (SIRI) predicts poor survival in pancreatic cancer patients treated with FOLFIRINOX Muhammad Bilal Razzaq Received Received
  168-P Maximum tolerated radiation dose for unresectable thoracic esophageal squamous cell carcinoma: both acute and late toxicities matter WEN YU Received Received
  169-P Apatinib as non-first-line treatment in patients with advanced cholangiocarcinoma. Jianzhen Lin Received Received
  170-P Nutritional index differential as a prognostic factor for recurrence in patients with locally advanced rectal cancer Ramos Maritza Received Received
  174-P Proposal of optimal cut-off of preoperative serum tumor marker levels to predict postoperative recurrences of gastric cancer Bin Sato Received Received
  175-P The optimal time interval between self-expandable metallic stent placement and elective operation in patients with obstructive colon cancers: a multicenter retrospective analysis. BONG-HYEON KYE Received Received
  176-P Multicenter phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil-resistant advanced gastric cancer (HGCSG1502) Tetsuhito Muranaka Received Received
  178-P A nomogram to predict poor health-related quality of life in metastatic colorectal cancer patients Vincenzo Formica Received Received
  179-P Retrospective analysis of 18 cases of gastric cancer with peritoneal metastases resulting in successful conversion surgery Rio Honma Received Received
  180-P A phase II study of capecitabine plus oxaliplatin therapy (XELOX) for patients with inoperable/advanced gastric cancer who were resistant/intolerable to fluoropyrimidine, CDDP, taxane, and CPT-11 (OGSG1403) Naotoshi Sugimoto Received Received
  181-P Efficacy of surgical resection in patients with recurrent tumor of intrahepatic cholangiocarcinoma Junichi Arita Received Received
  182-P Clinical importance of colonoscopy in patients with gastric cancer Hee chan Yang Received Received
  183-P Legumain is a predictive effector of peritoneal metastasis for diffuse gastric cancer patients Yan Wang Received Received
  184-P Calcium and vitamin D intake and colorectal cancer morbidity rates in Poland Miroslaw Jarosz Received Received
  185-P Is intra-arterial hepatic chemotherapy painful? Fouad Kerbage Received Received
  186-P Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers Andrea Mafficini Received Received
  188-P Hepatic sinusoidal obstruction syndrome (HSOS) in cStage III gastric cancer patients undergoing neoadjuvant chemotherapy with oxaliplatin: a retrospective cohort study Kiyotaka Kawaguchi Received Received
  191-P Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND) Jorge Aparicio Received Received
  192-P Complete peritonectomy versus ive peritonectomy in peritoneal carcinomatosis secondary to colorectal cancer: a prospective comparative analysis of outcomes ASHWIN KR Received Received
  193-P FOLFIRINOX after first-line gemcitabine-based chemotherapy in metastatic pancreatic cancer: a mono-institutional experience FRANCESCA FOSCHINI Received Received
  194-P Right vs left-sided RAS wild-type metastatic colorectal cancer treated with EGFR inhibitors: prognostic differences SÍlvia Duarte Received Received
  195-P Coffee and alcohol consumption and trends in colorectal cancer morbidity in Poland Miroslaw Jarosz Received Received
  198-P Predictors of morbidity and mortality for patients with peritoneal carcinomatosis secondary to colorectal cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy ASHWIN KR Received Received
  199-P Role of robotic surgery for rectal cancer: short-term, functional, and oncological outcomes for 150 consecutive patients ASHWIN KR Received Received
  200-P Assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer ASHWIN KR Received Received
  201-P Treatment of relapsed oesophagogastric adenocarcinoma after perioperative chemotherapy and surgery Michael Davidson Received Received
  203-P The role of combined treatment of metastatic colorectal cancer in patients with liver metastases Danila Gridnev Received Received
  204-P Procalcitonin can be used to predict not only postoperative infectious complications but also prognosis in colorectal cancer Junghoon Bae Received Received
  205-P Hepatocellular carcinoma: characteristics, outcomes, and prognostic fators Adriana Novais Lopes Monteiro Soares Received Received
  206-P Prognostic factors of metastatic colorectal cancer patients undergoing first-line chemotherapy plus bevacizumab Zoubida Behourah Received Received
  207-P Clinical and molecular characteristics of biliary tract carcinoma using next-generation sequencing Lucia Ceniceros Received Received
  208-P Phase II study in progress to verify improved response with mFOLFOX6 after exposure to an immune checkpoint inhibitor in advanced gastric cancer Ahn Ann Received Received
  209-P Sorafenib in patients with hepatocellular carcinoma: 10 years of real life Giulia Rovesti Received Received
  210-P Cytosponge for post-chemoradiation surveillance of oesophageal cancer: a feasibility study SOMNATH MUKHERJEE Received Received
  211-P A nomogram to predict neutropenia in metastatic pancreatic cancer patients treated with gemcitabine/nab-paclitaxel Cristina Morelli Received Received
  213-P CA19-9 decrease and predictive value for response in patients with metastatic pancreatic cancer treated with FOLFIRINOX José Francisco Rodríguez Hernández Received Received
  214-P Does PICC side matter? The experience at our hospital Ana Gil Torralvo Received Received
  215-P Recurrence rate in colorectal adenocarcinoma patients receiving adjuvant capecitabine monotherapy: do the number of chemotherapy cycles and relative dose intensity of the drug play a role? Joseph Sgouros Received Received
  216-P Neo-adjuvant Chemo-Radiation for Resectable Esophageal Carcinoma is Oral Capecitabine Non-Inferior to Paclitaxel Carboplatin Combination? ALOKE GHOSH DASTIDAR Received Received
  218-P L1CAM expression in colorectal cancer identifies patients prone to metastasis already in early-stage disease Athanasios Tampakis Received Received
  219-P Is there any affordable and reliable score in local gastric cancer? Antia Cousillas Received Received
  220-P Perioperative chemotherapy with FLOT vs other regimens for resectable gastric cancer Tamar Esakia Received Received
  221-P Locally advanced unresectable or metastatic pancreatic adenocarcinoma in patients under 65 years with good performance status (PS) at Ramón y Cajal University Hospital in Madrid Juan Jose Serrano Domingo Received Received
  222-P Patient-reported outcomes including LARS score and quality of life one year after chemoradiotherapy for anal cancer Karen-Lise Garm Spindler Received Received
  223-P Quality of life and preoperative chemotherapy in gastric cancer in Chile: results from the observational study of perioperative chemotherapy in gastric cancer (PRECISO) Bettina Mller Received Received
  224-P HEPANOVA phase 2 study design: Tumor Treating Fields concomitant with sorafenib for the treatment of advanced hepatocellular carcinoma James Wallis Received Received
  226-P Efficacy of first-line systemic therapy for left-sided primary metastatic colon cancer - Single-centre retrospective cohort analysis of 186 patients Juraj Prejac Received Received
  227-P Real World Data (RWD) of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): clinical benefit from a Spanish single institution. Alberto Sánchez-Camacho Mejias Received Received
  228-P Tumor Treating Fields (150 kHz) combined with FOLFOX inhibits gastric cancer in vitro James Wallis Received Received
  229-P The value of alfa-fetoprotein and neutrophil/lymphocyte ratio (NLR) in the prognosis of patients with hepatocellular carcinoma Catarina Quintela Received Received
  230-P EFFECTIVENESS OF CA 19.9 IN PREDICTING PROGNOSIS IN METASTATIC PANCREATIC CANCER PATIENTS TREATED WITH NAB-PACLITAXEL PLUS GEMCITABINE Stefano Mariani Received Received
  231-P Proinflammatory cytokines as predictive factors for response to chemotherapy or mental disorders present in colorectal cancer patients Pop Vlad Vasile Received Received
  232-P RENCA MACROBEAD THERAPY (RMB): A BIOLOGICAL-SYSTEMS APPROACH TO METASTATIC COLORECTAL CANCER U.S. FDA BB-IND 10091 Angelica Nazarian Received Received
  233-P Disparities in clinical outcomes across age, sex and race among patients with pancreatic adenocarcinoma: a single center experience Ravi Paluri Received Received
  235-P Induction Chemotherapy with Taxane versus Anthracycline-based Triplet for Locally Unresectable Nonmetastatic Gastric Cancer Clara Borges Received Received
  236-P Histological Patterns and Clinical Characteristics of Metastatic Gastric Adenocarcinoma, Single institutional Experience in The Eastern Province of Saudi Arabia Nedal Bukhari Received Received
  237-P Does metastatic colorectal cancer in elderly patients have specific features: the final results of a prospective phase II study of bevacizumab in combination with capecitabine as first-line treatment? Tomislav Omrcen Received Received
  238-P Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy Donna Stefanoni Received Received
  239-P Sorafenib for advanced hepatocellular carcinoma (HCC) in the public health setting in Brazil: a cost-effectiveness analysis Rafael Carmo Received Received
  240-P Outcomes of Gastrointestinal cancers treated on Phase 1 clinical trials at ONeal Comprehensive Cancer Center Ravi Paluri Received Received
  243-P A comparison of the utilization and efficacy of palliative chemotherapy for the treatment of locally advanced or metastatic gastroesophageal carcinoma: a retrospective single-center analysis Aysegl Ilhan-Mutlu Received Received
  245-P Neoadjuvant modified FOLFIRINOX or gemcitabine-nab paclitaxel followed by stereotactic body radiotherapy for patients with locally advanced pancreatic cancer Ravi Paluri Received Received
  246-P The importance of laterality in colorectal cancer predicting response to therapeutics retrospective study evaluating differences between right and left colon in stage IV colon cancer Élia Cipriano Received Received
  247-P SPLANCHNIC VEIN THROMBOSIS IN CHOLANGIOCARCINOMA. A RETROSPECTIVE OBSERVATIONAL STUDY. DONOSTIA UNIVERSITY HOSPITAL. ANA LANDA MAGDALENA Received Received
  248-P Futility and Utility of Two-stage Hepatectomy Miguel Cunha Received Received
  250-P The combined treatment of 150 kHz Tumor Treating Fields (TTFields) and sorafenib shows in vitro and in vivo efficacy in hepatocellular carcinoma James Wallis Received Received
  251-P FLOT versus ECF/ECX peri-operative regimens in real life setting for patients with resectable gastric adenocarcinoma Joana Graa Received Received
  253-P Age vs Performance Status - Which is worst for surgery outcome? Edgar Amorim Received Received
  254-P LIQUID BIOPSY FOR RAS MUTATIONAL STATUS ANALYSIS IN METASTATIC COLORECTAL CANCER JOANA MARINHO Received Received
  255-P Outcomes of treatment for non-metastatic rectal cancer; a ten year single institute experience at the Bank of Cyprus Oncology Centre (BOCOC) Ifigenia Konstantinou Received Received
  256-P Locally advanced unresectable and metastatic pancreatic cancer predictors of survival Élia Cipriano Received Received
  258-P Computational simulations to determine the effectiveness and thermal safety of tumor treating fields with delivery to the abdomen James Wallis Received Received
  259-P A novel anti-tumorigenic mechanism by herbal extract saikosaponin-d through p-STAT3/C/EBP signaling suppression of COX-2 in liver cancer Yiguang Lin Received Received
  260-P PANOVA phase 3 study design: Tumor Treating Fields (150 kHz) in combination with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (LAPC) James Wallis Received Received
  262-P Percutaneous transhepatic biliary drainage in malignant biliary obstruction: complications and outcome MANOJ KUMAR Received Received
  264-P Chinese herbal medicine Sijunzi decoction alleviates liver cancer cachexia through downregulating TGF- and IGF 1 signaling pathways Yan Chen Received Received
  265-P RETROPERITONEAL LYMPH NODE METASTASES AS A PROGNOSIS FACTOR IN OVERALL SURVIVAL IN METASTATIC COLORECTAL CANCER German Calderillo Received Received
  266-P Metastatic pancreatic cancer: Characteristics of long-term survivors margaret mandelson Received Received
  267-P Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer Tatiana Titova Received Received
  268-P Association between primary perioperative CEA ratio, tumor site, and overall survival in patients with colorectal cancer Anup Kasi Received Received
  269-P PIPAC PACLITAXEL: A SYSTEMATIC AND PERITONEAL TISSUE PHARMACOKINETIC STUDY IN SWINE Hon Lyn Tan Received Received
  271-P Efficacy and tolerability of the combination of Liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic cancers: post-approval clinic experience Anup Kasi Received Received
  272-P Is the gastroenterologist really necessary in the operating room? Intraoperative rectosigmoidoscopy: how we do it. Edgar Amorim Received Received
  274-P A MULTICENTER SPANISH RETROSPECTIVE STUDY OF PLATINUM-BASED CHEMOTHERAPY SENSITIVITY IN THE FIRST LINE SETTING AFTER RELAPSE FROM PERIOPERATIVE PLATINUM BASED CHEMOTHERAPY IN GASTRIC CANCER Luis Paul Del Carpio Huerta Received Received
  275-P Immune-inflammatory and clinicopathologic prognostic factors in a Western cohort of resected gastric cancers (GCs) Massimiliano Salati Received Received
  277-P Socioeconomic and Administrative Factors Associated with Health&8209;care Delay and Treatment of Esophageal and Gastric Carcinoma: Experience at a Tertiary Care Centre in a Developing Country SYED ADIL HASSAN Received Received
  279-P Characterization of mismatch repair deficiency in biliary tract cancer Caterina Vivaldi Received Received
  281-P EFFICACY OF A THERAPEUTIC EXERCISE PROGRAM ON AUTONOMIC NERVOUS SYSTEM FUNCTION, CARDIAC FUNCTION AND FUNCTIONAL CAPACITY IN COLORECTAL CANCER SURVIVORS: A RANDOMIZED CONTROLLED PILOT STUDY Julia Ruiz-Vozmediano Received Received
  283-P Predictors of Oxaliplatin-Induced Hepatotoxicity: Increase in Spleen Volume or Liver Fibrosis and Steatosis? Malek Kreidieh Received Received
  285-P The role of active nutritional intervention in patients receiving chemoradiation (CRT) for oesophageal cancer Rob Owens Received Received
  286-P The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with FIRST-LINE NAB-PACLITAXEL AND GEMCITABINE: POST-HOC ANALYSIS OF an Austrian multicenter, non-interventional study Jakob M. Riedl Received Received
  288-P The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA) Debora Basile Received Received
  289-P Incidence and severity of cancer-related fatigue in gastric cancer patients Bogdan Gafton Received Received
  290-P Comparative analyses between younger and older patients with pancreatic adenocarcinoma: differences in clinicopathological features, treatment patterns, and outcomes Kunal Kadakia Received Received
  291-P NRG1-fusion positive gastrointestinal tumours: Afatinib as a novel potential treatment option Benjamin Weinberg Received Received
  293-P EVALUATION OF NEOANGIOGENESIS IN LOCALLY ADVANCED GASTRIC CANCER BEFORE AND AFTER NEOADJUVANT RADIOCHEMOTHERAPY BY PROBE CONFOCAL LASER ENDOMICROSCOPY (PCLE) Renato Cannizzaro Received Received
  294-P Role of chemoradiation (CRT) in the adjuvant treatment of radically resected pancreatic cancer (PC) patients (pts): a mono-institutional retrospective analysis Lisa Salvatore Received Received
  296-P Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience Andrea Pretta Received Received
  297-P Serum level of miRNA-143 as a potential prognostic marker in patients with colorectal cancer and synchronous metastatic disease Maria Radanova Received Received
  298-P Directed differentiation of human pluripotent stem cells into hepatic tissue with gallbladder and bile ducts organoids in vitro Fenfang Wu Received Received
  299-P Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients Silvia Catanese Received Received
  300-P Pancreatic Cancer resection in elderly patients: Analysis of outcomes MARIANA GARCÍA VIROSTA Received Received
  302-P Prospective Evaluation of FOLFIRINOX in Neo-adjuvant Treatment of Gastro-Oesophageal Junction Carcinomas Nicholas Travers Received Received
  303-P Third-line re-treatment of advanced pancreatic adenocarcinoma with gemcitabine and nab-paclitaxel Adarsh Das Received Received
  304-P Modified FOLFIRINOX as a second-line treatment in pancreatic adenocarcinoma following gemcitabine plus nab-paclitaxel failure in patients with performance status two or less Adarsh Das Received Received
  305-P K-Ras mutation in liquid biopsy and tumor tissue correlation in patients with pancreatic cancer EDUARDO JOSÉ PERDOMO ZALDIVAR Received Received
  306-P Anal cancer outcomes and human immunodeficiency virus: a single-center experience Carmen García Durán Received Received
  307-P Epidemiology, treatment and prognostic factors of colorectal cancers in Tunisia: compliance with recommendations and therapeutic results Sarra Karrit Received Received
  308-P Role of TILS in predicting evolution of metastatic colorectal cancer sonia ben nasr Received Received
  310-P Efficacy of FOLFIRI as a second-line in extrapulmonary poorly-differentiated neuroendocrine carcinoma Carles Fabregat Franco Received Received
  314-P Do we need adjuvant therapy in patients with rectal cancer and pathologic complete response, after conventional preoperative chemoradiation and laparoscopic (LapTME) or Transanal total mesorectal excision (TaTME)? ROXANA REYES Received Received
  315-P ?Np73 and ?133p53 in liquid biopsy as early diagnostic markers for colorectal cancer Javier Rodríguez-Cobos Received Received
  316-P Outcomes of gastrointestinal tumours in the tyrosine kinase inhibitor era: 15 years of experience from a single tertiary care centre in India. Prabhat Bhargava Received Received
  317-P Clinical, pathological, and prognostic features of rare BRAF mutations in metastatic colorectal cancer: a bi-institutional retrospective analysis (REBUS study) Maria Bensi Received Received
  319-P Longitudinal evaluation of angiogenesis-related circulating biomarkers during second-line treatment with paclitaxel and ramucirumab in advanced gastroesophageal cancer Lorenzo Fornaro Received Received
  320-P Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: real-world data of 13 oncological centers in Portugal Tiago Cruz Tomás Received Received
  321-P Young Onset Rectal Cancer: a Therapeutic Challenge Debapriya Mondal Received Received
  323-P Is FNA always necessary in submucosal lesion miming GIST? Renato Cannizzaro Received Received
  324-P Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Experience Rojymon Jacob Received Received
  326-P CLINICAL PRACTICE USE OF LIQUID BIOPSY TO IDENTIFY RAS/BRAF MUTATIONAL STATUS IN PATIENTS WITH METASTATIC COLORECTAL CANCER (mCRC): A SINGLE INSTITUTION EXPERIENCE Vincenzo De Falco Received Received
  327-P Exploration of alternative regorafenib regimens to manage hand-foot-skin-reaction OPEN HEALTH MEDICAL COMMUNICATIONS Received Received
  328-P Treatment of Metastatic Colorectal Cancer in the Real World (mCRC): Final Results from a European Survey Zorana Maravic Received Received
  330-P Retrospective study of Regorafenib versus Trifluridine/Tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: a single Italian institution real-life clinical data Pasquale Vitale Received Received
  331-P Paclitaxel plus ramucirumab combination therapy as second-line therapy in elderly patients with metastatic advanced gastric cancer: A single-center retrospective study. Tomomi Kashiwada Received Received
  332-P A new prognostic score for biliary tract cancer: a multicenter experience Pina Ziranu Received Received
  333-P Early fluorescence detection of oropharengeal and esophageal cancer Rasul Sadykov Received Received
  335-P FOLFIRINOX versus Nab-paclitaxel plus gemcitabine in the first-line chemotherapy for patients with advanced pancreatic ductal adenocarcinoma: a multivariate analysis of prognostic factors in a national cohort (Comunica-TTD working group). Federico Longo Muñoz Received Received
  339-P Epidemiology, treatment modalities and prognostic factors of colon cancer in the central region of Tunisia Imtinen Belaid Received Received
  341-P Health disparities and gastric cancer survival in Cali, Colombia: a hospital-based study Angela Zambrano Received Received
  344-P Survival analysis of gastric cancer in a Hispanic population: 15-years of experience at a specialized cancer center Angela Zambrano Received Received
  346-P A single center experience with oral chemotherapy with capecitabine and temozolomide in metastatic neuroendocrine tumors Ines Rego Received Received
  347-P THE RISK OF HEPATITIS B VIRUS (HBV) REACTIVATION IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS (GIST) UNDER IMATINIB MESYLATE TREATMENT DIMITRIOS TZILVES Received Received
  348-P Esophageal cancer: about 42 cases Experience of the medical oncology department of Hassan II University Hospital of Fez, Morocco Nouiakh Lamyae Received Received
  350-P Management of gallbladder cancer - EXPERIENCE OF MEDICAL ONCOLOGY DEPARTMENT ABOUT 140 CASES Nouiakh Lamyae Received Received
  352-P Prognostic Value, Clinicopathologic Features and Diagnostic Accuracy of Interleukin-8 in Colorectal Cancer: A prospective study in 60 patients in Tunisia. Sarra Karrit Received Received
  353-P Neurotoxicity of oxaliplatin in patients treated for colorectal cancer: FOLFOX versus XELOX Hanane Fatima Zahra Aliane Received Received
  354-P Survival and prognostic factors of localized gastric carcinomas (about 50 cases). Experience of the medical oncology department of Hassan II University of Fez hayat erraichi Received Received
  355-P To investigate the role of PGD2 and its receptor signalling in colon cancer pathophysiology Pujarini Dash Received Received
  356-P COLORECTAL CANCER IN YOUNG TUNISIAN PATIENTS: clinical, histopathological and RAS testing data HAYFA GUETTITI TOUNSI Received Received
  357-P The place of oncogeriatric evaluation in the therapeutic management and the prediction of the toxicity of the specific medical treatment of elderly patients with colorectal cancer Hanane Fatima Zahra Aliane Received Received
  362-P Reasons for chemotherapy discontinuation and end of life in gastro-intestinal cancers: a multicentric prospective AGEO study Solene Doat Received Received
  364-P High expression of oestrogen receptor beta correlates with anti-tumorigenic inflammatory proteins in colorectal cancer. Geriolda Topi Received Received
  366-P Diagnostic and prognostic value of P53 and the human Programmed cell death 4 (PDCD-4) genes in colorectal cancer Enas Elkhouly Received Received
  367-P Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in malignant peritoneal disease: a review on outcomes for colorectal cancer Joana Simes Received Received
  368-P Chemoradiation and surgery versus chemoradiation followed by neoadjuvant chemotherapy and surgery in locally advanced rectal cancer: a retrospective analysis of a single center experience Bárbara Lima Received Received
  369-P Home chemotherapy in colorectal cancer: First experience in Argentina guillermo streich Received Received
  370-P Role of radiotherapy in local control of metastatic rectal cancer: a single-center experience Ana Afonso Received Received
  371-P Feasibility of modulated electro-hyperthermia as a concomitant boost to preoperative radiotherapy in locally advanced rectal cancer: A phase 2 trial Seihwan You Received Received
  375-P Palliative management of malignant biliary obstruction in patients with advanced biliary tract cancers SOUMIA berrad Received Received
  376-P Primary malignant tumors of the small intestine: clinical and therapeutic aspects SOUMIA berrad Received Received
  381-P The management of neuroendocrine gastroenteropancreatic tumors. SOUMIA berrad Received Received
  382-P Clinicopathologic feature of microsatellite stable early-onset colorectal cancer Rumi Shin Received Received
  383-P Survival and prognostic factors for stage II colon cancer SOUMIA berrad Received Received
  384-P Anal Carcinoma A comparative analysis of the standard treatment vs An hypofractionated schedule (the Tlalpan Regime) experience at the Instituto Nacional de Cancerología, México. Jesús Zamora Received Received
  385-P PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib Long Pan Received Received
  389-P Clinical Significance of BRAF Mutations in Colorectal Cancer: A Retrospective Study of One Institution in a real-life population. Lidia Carnerero Córdoba Received Received
  392-P Minimally invasive surgical approach for the treatment of esophageal cancer as a component of multimodal treatment Yestay Abzalbek Received Received
  395-P Expression of MMR in Women High Grade Carcinoma of Unknown Primary Joni Howells Received Received
  398-P The use of first, second and beyond line chemotherapy for metastatic pancreatic ductal adenocarcinoma at the Royal Marsden Hospital Michael Davidson Received Received
  399-P How does adjuvant chemotherapy for stage II colon cancer impact survival in regard of prognostic factors? A report of 147 Tunisian cases Syrine SGHAIER Received Received
  402-P Incidence and mortality rates of cholangiocarcinoma in England Tracey Genus Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Fri 8:00-15:00
22:55
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image
 

ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO 21st World Congress on Gastrointestinal Cancer

 

3-6 July 2019 Barcelona
HELP LINE
Manage Orders
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 06/07/2019 TO 03/07/2020
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.21wcgic.2019 
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 02/07/2019
Upload Poster
Upload Oral Presentation of Video
Check your Poster
Upload
Poster
Upload Oral
Presentation or Video
Check
your Poster




PosterSessionOnline
Logo Draft
 
Logo Cert